Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparative PK Study of PF-06410293 and Adalimumab in Healthy Subjects
NCT02237729Phase 1Completed
- Sponsor
- Pfizer
- Start
- Sep 2014
- Primary completion
- Mar 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of adalimumab in rheumatoid arthritis (RA) (3 arms), sponsored by Pfizer. Primary endpoints: Maximal Serum Concentration, Area Under the Concentration Time Curve from Time 0 to 2 Weeks and 2 more. Started Sep 2014; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02237729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02237729.